Evaluation of ABBV-383 for Safety and Efficacy in Patients with Light Chain Amyloidosis

The primary objective of this study is to evaluate the **safety** and **efficacy** of ABBV-383 in subjects diagnosed with **Light Chain Amyloidosis**. This condition is characterized by the deposition of amyloid fibrils derived from immunoglobulin light chains, leading to organ dysfunction. Assessing the safety profile and therapeutic effectiveness of ABBV-383 is clinically significant as it may offer a potential treatment option for managing this rare and serious disease. No secondary objectives are provided for this study.

The clinical trial involves a total of **60 participants** diagnosed with **Light Chain Amyloidosis**. The study population includes both male and female subjects, with an age range spanning from 18 to 65 years. Participants were selected to represent a diverse group, including individuals from vulnerable populations. The general health status of the participants is not specified, but they are likely to be affected by the condition under study. Lifestyle considerations such as diet, physical activity, and habits are not detailed in the available data. The selection process and specific inclusion or exclusion criteria are not provided by the sponsor.

The clinical trial is designed to evaluate the safety and efficacy of the investigational product ABBV-383 in subjects diagnosed with **Light Chain Amyloidosis**. This study is structured as a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date is February 29, 2024, with an anticipated completion date of June 29, 2028. Participants will be involved in the study for the duration of the trial, which spans approximately four years, unless early termination criteria are met.

The trial will commence with an inclusion visit, also known as the screening visit, where potential participants will be assessed against the inclusion and exclusion criteria to determine eligibility. Following successful enrollment, participants will undergo a series of study visits at predetermined intervals. These visits are designed to monitor the safety and efficacy of the treatment, collect data, and ensure adherence to the study protocol. The sequence of visits will include regular follow-up assessments, which are critical for evaluating the ongoing health status of the participants and the therapeutic impact of the investigational product.

The end-of-study visit will mark the conclusion of a participant's involvement in the trial. During this visit, final assessments will be conducted to gather comprehensive data on the long-term effects of the treatment. Participants may be withdrawn from the study prior to its completion if they experience adverse events, fail to comply with the study protocol, or choose to withdraw consent. The trial's design and procedures are meticulously crafted to ensure the collection of robust and reliable data, contributing to the understanding of the investigational product's potential benefits and risks in treating Light Chain Amyloidosis.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on February 29, 2024, with an estimated completion date of June 29, 2028. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology to measure, collect, and analyze these efficacy parameters at predetermined timepoints throughout the study duration. The trial's design and execution will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy assessments. The trial phase indicates a focus on confirming the effectiveness of the intervention in a larger population, following initial safety and efficacy evaluations in earlier phases.